Accession Number:

ADA504964

Title:

Enhancing Quality of Life for Breast Cancer Patients with Bone Metastases

Descriptive Note:

Annual summary rept. 15 Mar 2007-14 Mar 2008

Corporate Author:

SYRACUSE UNIV RESEARCH FOUNDATION NY

Personal Author(s):

Report Date:

2008-04-01

Pagination or Media Count:

47.0

Abstract:

Current treatment for osteolytic breast cancer bone metastasis typically involves radiation therapy RTX to palliate bone pain and a bisphosphonate to inhibit osteoclastic bone resorption. The goal of this research was to determine the effects of zoledronic acid as an adjunct to RTX on restoring bone strength and density. We also investigated whether the combination of ZA and an anabolic agent parathyroid hormone, PTH as adjuncts to RTX further enhanced bone strength and thus decrease the risk of subsequent pathological fractures.

Subject Categories:

  • Anatomy and Physiology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE